Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
24 January 2018
E-000365-18
Question for written answer
to the Commission
Rule 130
Cristian-Silviu Buşoi (PPE)

 Subject:  Medicine shortages

Despite the policy measures implemented (in the shape of Article 81 of Directive 2001/83/EC) to prevent pharmaceutical shortages, several Member States, especially newer Member States such as Romania, are still facing considerable issues.

Pharmaceutical shortages are driven by many factors, among them parallel trade, manufacturing or distribution, illegitimate business strategies, the price of medicines and red tape, eventually impacting directly on European patients.

Given that ensuring patients’ access to medicines is a key objective of the EU and the WHO and of UN Sustainable Development Goal 3, what further steps does the Commission intend to take to strengthen the policy framework and tackle pharmaceutical shortages effectively across all Member States?

Last updated: 7 February 2018Legal notice